CL2021000033A1 - Nuevos compuestos - Google Patents
Nuevos compuestosInfo
- Publication number
- CL2021000033A1 CL2021000033A1 CL2021000033A CL2021000033A CL2021000033A1 CL 2021000033 A1 CL2021000033 A1 CL 2021000033A1 CL 2021000033 A CL2021000033 A CL 2021000033A CL 2021000033 A CL2021000033 A CL 2021000033A CL 2021000033 A1 CL2021000033 A1 CL 2021000033A1
- Authority
- CL
- Chile
- Prior art keywords
- new compounds
- diseases
- new
- human
- pharmaceuticals
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000019206 urinary tract infection Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen en la presente memoria nuevos compuestos y composiciones de C-manósido y su aplicación como productos farmacéuticos para el tratamiento de enfermedades humanas. También se proporcionan métodos para inhibir la actividad de FimH en un sujeto humano con el fin de tratar enfermedades, tales como infección del tracto urinario.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862695993P | 2018-07-10 | 2018-07-10 | |
US201862755588P | 2018-11-05 | 2018-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000033A1 true CL2021000033A1 (es) | 2021-07-30 |
Family
ID=67957191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000033A CL2021000033A1 (es) | 2018-07-10 | 2021-01-07 | Nuevos compuestos |
Country Status (24)
Country | Link |
---|---|
US (3) | US11111262B2 (es) |
EP (1) | EP3820856B9 (es) |
JP (2) | JP7309862B2 (es) |
KR (1) | KR20210031682A (es) |
CN (1) | CN112334455B (es) |
AU (1) | AU2019301946B2 (es) |
BR (1) | BR112021000370A2 (es) |
CA (1) | CA3105940A1 (es) |
CL (1) | CL2021000033A1 (es) |
DK (1) | DK3820856T3 (es) |
ES (1) | ES2928634T3 (es) |
HR (1) | HRP20221381T1 (es) |
HU (1) | HUE060140T2 (es) |
IL (1) | IL279993B2 (es) |
LT (1) | LT3820856T (es) |
MX (1) | MX2021000340A (es) |
PH (1) | PH12020551905A1 (es) |
PL (1) | PL3820856T3 (es) |
PT (1) | PT3820856T (es) |
RS (1) | RS63712B1 (es) |
SG (1) | SG11202011066XA (es) |
TW (1) | TWI821328B (es) |
UY (1) | UY38293A (es) |
WO (1) | WO2020012336A1 (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11560388B2 (en) | 2019-03-19 | 2023-01-24 | Boehringer Ingelheim Vetmedica Gmbh | Anthelmintic aza-benzothiophene and aza-benzofuran compounds |
US11964977B2 (en) | 2020-05-29 | 2024-04-23 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic heterocyclic compounds |
US11999742B2 (en) | 2021-11-01 | 2024-06-04 | Boehringer Ingelheim Vetmedica Gmbh | Substituted pyrrolo[1,2-b]pyridazines as anthelmintics |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3105940A1 (en) * | 2018-07-10 | 2020-01-16 | Glaxosmithkline Intellectual Property Development Limited | C-mannoside compounds useful for the treatment of urinary tract infections |
CN113461753B (zh) | 2020-03-31 | 2023-05-23 | 郑计岳 | 2-炔基甘露糖衍生物及其应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5122602A (en) | 1989-02-13 | 1992-06-16 | Miles Inc. | Chromogenic merocyanine enzyme substrates |
US6420127B1 (en) | 1994-11-18 | 2002-07-16 | Washington University | Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections |
DK0730601T3 (da) | 1993-11-18 | 2005-06-06 | Univ Washington | Forbindelser og farmaceutiske præparater til behandling af profylakse af bakterieinfektioner |
EP1192038B1 (en) | 1999-06-28 | 2003-11-05 | Lear Corporation | Method of forming a blow-molded plastic part having a living hinge |
WO2001010386A2 (en) | 1999-08-11 | 2001-02-15 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
EP1303256B1 (en) | 2000-06-09 | 2009-01-07 | Baylor College of Medicine | The combination of antimicrobial agents and bacterial interference to coat medical devices |
AU2003274127A1 (en) | 2003-10-08 | 2005-04-21 | Innovaprotean, S.L. | Compounds for the treatment of diseases associated with the formation of amyloid fibrils |
EP1755619A2 (en) | 2004-03-23 | 2007-02-28 | VIB vzw | Anti-adhesive compounds to prevent and treat bacterial infections |
SE528382C2 (sv) | 2004-10-05 | 2006-10-31 | Probi Ab | Probiotiska lactobacillusstammar för förbättrad vaginal hälsa |
FR2876798A1 (fr) | 2004-10-14 | 2006-04-21 | Univ Clermont Auvergne | Diagnostic et traitement de la maladie de crohn |
WO2011050323A1 (en) | 2009-10-22 | 2011-04-28 | The Washington University | Compounds and methods for treating bacterial infections |
AU2010333017B2 (en) | 2009-12-14 | 2016-06-16 | University Of Basel | Mannose derivatives as antagonists of bacterial adhesion |
ES2732311T3 (es) | 2011-02-07 | 2019-11-21 | Univ Washington | Compuestos de manósidos y procedimientos de uso de los mismos |
WO2012164074A1 (en) | 2011-06-03 | 2012-12-06 | University Of Basel | Mannose phosphate derivatives as antagonists of bacterial adhesion |
US20130261077A1 (en) | 2012-03-07 | 2013-10-03 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
EP2690105A1 (en) | 2012-07-24 | 2014-01-29 | Centre National De La Recherche Scientifique | Mannose derivatives, a process for preparing the same and their uses as a drug |
US20140107049A1 (en) | 2012-10-04 | 2014-04-17 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
PL2935302T3 (pl) | 2012-12-18 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Pochodne mannozy do leczenia infekcji bakteryjnych |
CA2905019C (en) | 2013-03-12 | 2021-07-06 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
WO2014194270A1 (en) | 2013-05-30 | 2014-12-04 | Washington University | Compounds and methods for treating bacterial infections |
JP6961572B2 (ja) | 2015-08-05 | 2021-11-05 | アンテローム | 付着性大腸菌と関連する病状の処置に有用なマンノース誘導体 |
JP2019508504A (ja) * | 2016-03-11 | 2019-03-28 | フィンブリオン セラピューティックス, インコーポレイテッドFimbrion Therapeutics, Inc. | 疾病の処置に有用なc−グリコシド化合物 |
CA3018345A1 (en) | 2016-03-23 | 2017-09-28 | Fimbrion Therapeutics, Inc. | Mannose-derived antagonists of fimh useful for treating disease |
AU2018351471A1 (en) | 2017-10-16 | 2020-05-07 | Enterome | New tools for assessing FimH blockers therapeutic efficiency |
CA3105940A1 (en) * | 2018-07-10 | 2020-01-16 | Glaxosmithkline Intellectual Property Development Limited | C-mannoside compounds useful for the treatment of urinary tract infections |
-
2019
- 2019-07-08 CA CA3105940A patent/CA3105940A1/en active Pending
- 2019-07-08 UY UY0001038293A patent/UY38293A/es not_active Application Discontinuation
- 2019-07-08 PT PT197692205T patent/PT3820856T/pt unknown
- 2019-07-08 MX MX2021000340A patent/MX2021000340A/es unknown
- 2019-07-08 ES ES19769220T patent/ES2928634T3/es active Active
- 2019-07-08 TW TW108123912A patent/TWI821328B/zh active
- 2019-07-08 IL IL279993A patent/IL279993B2/en unknown
- 2019-07-08 CN CN201980042125.1A patent/CN112334455B/zh active Active
- 2019-07-08 LT LTEPPCT/IB2019/055806T patent/LT3820856T/lt unknown
- 2019-07-08 RS RS20221021A patent/RS63712B1/sr unknown
- 2019-07-08 HU HUE19769220A patent/HUE060140T2/hu unknown
- 2019-07-08 BR BR112021000370-3A patent/BR112021000370A2/pt unknown
- 2019-07-08 JP JP2021517745A patent/JP7309862B2/ja active Active
- 2019-07-08 HR HRP20221381TT patent/HRP20221381T1/hr unknown
- 2019-07-08 SG SG11202011066XA patent/SG11202011066XA/en unknown
- 2019-07-08 PL PL19769220.5T patent/PL3820856T3/pl unknown
- 2019-07-08 WO PCT/IB2019/055806 patent/WO2020012336A1/en active Application Filing
- 2019-07-08 KR KR1020217000328A patent/KR20210031682A/ko not_active Application Discontinuation
- 2019-07-08 EP EP19769220.5A patent/EP3820856B9/en active Active
- 2019-07-08 DK DK19769220.5T patent/DK3820856T3/da active
- 2019-07-08 AU AU2019301946A patent/AU2019301946B2/en active Active
-
2020
- 2020-10-06 US US17/063,947 patent/US11111262B2/en active Active
- 2020-11-06 PH PH12020551905A patent/PH12020551905A1/en unknown
-
2021
- 2021-01-07 CL CL2021000033A patent/CL2021000033A1/es unknown
- 2021-07-09 US US17/371,419 patent/US11697665B2/en active Active
-
2022
- 2022-10-03 JP JP2022159832A patent/JP7483820B2/ja active Active
-
2023
- 2023-04-28 US US18/308,842 patent/US20230287028A1/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11560388B2 (en) | 2019-03-19 | 2023-01-24 | Boehringer Ingelheim Vetmedica Gmbh | Anthelmintic aza-benzothiophene and aza-benzofuran compounds |
US11964977B2 (en) | 2020-05-29 | 2024-04-23 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic heterocyclic compounds |
US11999742B2 (en) | 2021-11-01 | 2024-06-04 | Boehringer Ingelheim Vetmedica Gmbh | Substituted pyrrolo[1,2-b]pyridazines as anthelmintics |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021000033A1 (es) | Nuevos compuestos | |
CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
NI201800124A (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
EA201692334A1 (ru) | Кортикостероидные композиции для местного применения | |
MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
BR112017017599A2 (pt) | métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal | |
EA201891007A1 (ru) | Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца | |
CO2017003321A2 (es) | Inhibidores de gingipaina de lisina | |
EA201490637A1 (ru) | Растительные стероиды и их применения | |
BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos | |
BR112022003659A2 (pt) | Composições e métodos de tratamento de doenças vasculares | |
MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
MX2018011539A (es) | Tratamiento de dolencias y enfermedades cutaneas asociadas a biopeliculas microbianas. | |
CR20110438A (es) | Icam 1 soluble como biomarcador para predicción de respuesta terapéutica | |
MX2020006075A (es) | Composiciones farmaceuticas de bendamustina. | |
EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
AR107460A1 (es) | Gabapentina oftálmica para el tratamiento de las úlceras corneales | |
NI201200196A (es) | Agentes terapéuticos 976 | |
BR112022008856A2 (pt) | Terapia combinada para doenças musculares | |
MX2018013885A (es) | Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3). | |
BR112021022281A2 (pt) | Novos compostos |